Risk factor
Limited trading liquidity
Profitability factor
Very strong margins and returns
About
Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of REG1V.HE is 22 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell